Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study) - Summary - MDSpire

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • By

  • Nabil E. Omar

  • Shereen Elazzazy

  • Anas Hamad

  • Mohamed Omar Saad

  • Aya Alasmar

  • Sahar M. Nasser

  • Maria Benkhadra

  • Hebatalla M. Afifi

  • Farah I. Jibril

  • Rawan A. Dawoud

  • Mohamed S. Hamid

  • Afnan Alnajjar

  • Arwa O. Sahal

  • Amaal Gulied

  • Hazem Elewa

  • June 19, 2026

  • 0 min

Share

Objective:

To correct the omission of a funding statement in the original publication regarding the SAFE-ICI-Q study.

Key Findings:
  • The publication of the article was funded by the Qatar National Library.
Interpretation:

The original article has been updated to include the omitted funding statement.

Conclusion:

The erratum serves to acknowledge the funding source that was previously unmentioned.

Sources:

Original Source(s)

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • by Nabil E. Omar, Shereen Elazzazy, Anas Hamad, Mohamed Omar Saad, Aya Alasmar, Sahar M. Nasser, Maria Benkhadra, Hebatalla M. Afifi, Farah I. Jibril, Rawan A. Dawoud, Mohamed S. Hamid, Afnan Alnajjar, Arwa O. Sahal, Amaal Gulied, Hazem Elewa

  • June 19, 2026

Related Content

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma

Neural regulation of tumor progression: implications for hepatocellular carcinoma